Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

202.08 +1.20 (+0.60%)
Official Closing Price Updated: 7:00 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
74 75 Next >
Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke
The company is still figuring out how to gain share in a market topped by AbbVie. 
Via Investor's Business Daily
7 Safe and Steady Dividend Stocks to Buy for Volatile Time
Discover how these seven standout companies offer both security and growth potential in an uncertain financial landscape. 
Via InvestorPlace
The Breakthrough Therapy Aiming To Solve The World’s Mental Health Crisis
EQNX::TICKER_START (NYSE:JNJ),(NYSE:ABBV),(NASDAQ:ATAI),(NASDAQ:CMPS),(NASDAQ:MNMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Economy
Exposures Economy Product Safety
The Top 7 Underrated Dividend Stocks Yielding 3% or More
Investors seeking dependable income and upside should buy these dividend stocks yielding 3% or more, the sooner the better 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
This Is What Whales Are Betting On AbbVie
Via Benzinga
Here's How Much $1000 Invested In AbbVie 10 Years Ago Would Be Worth Today
Via Benzinga
2 Dividend Kings to Buy on the Dip and Hold Forever
Don't ignore these stocks just because the rest of the market is. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why Is Immuno-Oncology Firm Harpoon Therapeutics Stock Trading Lower Today?
Harpoon Therapeutics Inc (NASDAQ: HARP) shares are trading lower after AbbVie Inc (NYSE: ABBV) chose not to exercise its exclusive license option within the Development and Option Agreement... 
Via Benzinga
AbbVie Unusual Options Activity For September 13
Via Benzinga
2 Undervalued Dividend Stocks to Buy Now
These two pharma titans are proven income vehicles. 
Via The Motley Fool
High Yield, Low Beta Stocks to Buy for the Next Market Meltdown
The market is set up for a fall, and it may start soon, as soon as the CPI data is released. These low-beta stocks are poised to outperform and pay dividends 
Via MarketBeat
Topics Economy Stocks
Exposures Economy Interest Rates US Equities
(ABBV) - Analyzing AbbVie's Short Interest
Via Benzinga
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Another Arthritis Blockbuster Drug Faces Generic Competition: Novartis' Sandoz Inks Pact With Samsung Bioepis
Sandoz, a generic and biosimilar medicines unit of Novartis AG (NYSE: NVS), has  
Via Benzinga
Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease
Data readout expected in Q4 2024 
From Alector, Inc.
Via GlobeNewswire
3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains
These biotech stocks to buy and hold offer tremendous upside blending long-term potential with healthcare advances. 
Via InvestorPlace
The Truth About IPO Investing
When most companies go public, they are somewhat mature. Tech company initial public offerings, or IPOs, are a bit different, however. These companies are often not yet profitable. And biotech IPOs are... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Could CVS Make a Copy of Ozempic?
Given its new biosimilars unit, copying Ozempic is more likely than it sounds. 
Via The Motley Fool
3 No-Brainer Dividend Stocks to Buy in September
Income investors should really like these biopharma stocks with juicy dividends. 
Via The Motley Fool
8 Pharma Stocks Affected by New Drug Price Negotiation Rules
Which companies have the most to lose now that Medicare can negotiate directly with them on the prices of some of the most widely used drugs? 
Via The Motley Fool
CVS Just Made a Major New Announcement, But Should You Buy It?
Spinning up a new division will probably be a boon for shareholders. 
Via The Motley Fool
The 3 Most Promising Biotech Stocks to Own Now
These top biotech stock picks with high and leading growth potential are must-owns for investors looking for high upside potential. 
Via InvestorPlace
Medicare Will Soon Negotiate Some Drug Prices. Is This a Threat to Johnson & Johnson's Earnings?
The healthcare giant's immunology drug Stelara brought in more than $9 billion in revenue last year. 
Via The Motley Fool
A Significant Reversal is in Sight for These 5 Med Tech Companies
Med tech stocks are down YOY despite strong secular tailwinds, cash flow, and dividends; the downturn in action is an opportunity and reversal is at hand. 
Via MarketBeat
What Impact Will Medicare Price Negotiations Have on Big Pharma Stocks?
Investors appear to be yawning for the most part at the latest news on Medicare drug price negotiations. 
Via The Motley Fool
Now or Never: 7 Blue-Chip Stocks Offering a Once-in-a-Lifetime Opportunity
If you're looking for a once-in-a-lifetime investment opportunity, consider these seven blue-chip stocks to buy now. 
Via InvestorPlace
Important Data Ahead, Tesla Turning On Massive Nvidia Cluster, 10 Drugs Name For Price Cuts
To gain an edge, this is what you need to know today. 
Via Benzinga
Nearing Retirement? These Stocks Will Pay You For Life
These companies are passive income machines. 
Via The Motley Fool
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.